Replimune Group (REPL) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free REPL Stock Alerts $6.72 -0.09 (-1.32%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 2:17 PM | investorplace.comREPL Stock Earnings: Replimune Group Misses EPS for Q4 2024May 16 at 8:00 AM | globenewswire.comReplimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate UpdateApril 19, 2024 | marketbeat.comVontobel Holding Ltd. Takes $2.58 Million Position in Replimune Group, Inc. (NASDAQ:REPL)Vontobel Holding Ltd. bought a new position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 305,412 shares of the company's stock, valued at approximately $2,575,000. Vontobel HoldApril 10, 2024 | marketbeat.comVanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)Vanguard Group Inc. grew its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 10.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,596,119 shares of the company's stock after buying an additional 242,220 shares during the period. VanguardApril 7, 2024 | globenewswire.comInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual MeetingApril 4, 2024 | globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 30, 2024 | bizjournals.comFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingMarch 29, 2024 | uk.investing.comReplimune appoints new CEO ahead of drug applicationMarch 28, 2024 | bizjournals.comPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealMarch 26, 2024 | marketwatch.comReplimune Names Sushil Patel as CEO in Broader ShakeupMarch 26, 2024 | markets.businessinsider.comReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOMarch 26, 2024 | globenewswire.comReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership TransitionsMarch 21, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 5.3%Replimune Group (NASDAQ:REPL) Trading 5.3% HigherMarch 16, 2024 | finance.yahoo.comREPL Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comREPL Mar 2024 10.000 putMarch 6, 2024 | finance.yahoo.comReplimune to Present at the American Association for Cancer Research Annual Meeting 2024March 5, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Redmile Group LLCRedmile Group LLC lowered its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 5.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,163,922 shares of the company's stock after sellingMarch 5, 2024 | finance.yahoo.comReplimune to Present at Three Upcoming Investor ConferencesFebruary 19, 2024 | marketbeat.comFY2024 Earnings Estimate for Replimune Group, Inc. (NASDAQ:REPL) Issued By HC WainwrightReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings estimates for shares of Replimune Group in a research report issued to clients and investors on Thursday, February 15th. HC Wainwright analyst R. Burns now forecasts that the company wFebruary 16, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Holdings Decreased by Lord Abbett & CO. LLCLord Abbett & CO. LLC lowered its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 82.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 184,419 shares of the company's stock after selling 854,087 sharFebruary 15, 2024 | markets.businessinsider.comPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy TrialsFebruary 12, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Expected to Post Q3 2025 Earnings of ($0.71) Per ShareReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Research analysts at Wedbush issued their Q3 2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on Thursday, February 8th. Wedbush analyst R. Driscoll anticipates that the company will post earnings of ($0.February 9, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPSReplimune Group (NASDAQ:REPL - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.12.February 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)February 9, 2024 | msn.comReplimune Group Is Worried About This – Should You Be Worried Too?February 9, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Up 4%Replimune Group (NASDAQ:REPL) Shares Up 4%February 8, 2024 | finance.yahoo.comReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateFebruary 8, 2024 | finance.yahoo.comReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash RunwayFebruary 8, 2024 | investing.comReplimune Group Inc (REPL)February 7, 2024 | marketwatch.comDisc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations ChiefJanuary 23, 2024 | seekingalpha.comReplimune: The Fall Is Justified, As Virus Therapy Fails Again In CancerJanuary 18, 2024 | marketbeat.comTD Asset Management Inc Boosts Stake in Replimune Group, Inc. (NASDAQ:REPL)TD Asset Management Inc increased its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 100.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 267,646 shares of the company's stock after purchasing an additional 133,823 shares duringJanuary 13, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Sees Significant Increase in Short InterestReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,690,000 shares, an increase of 45.8% from the December 15th total of 5,960,000 shares. Approximately 20.0% of the company's stock are short sold. Based on an average daily trading volume, of 1,500,000 shares, the days-to-cover ratio is presently 5.8 days.December 28, 2023 | finance.yahoo.comReplimune to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2023 | ca.finance.yahoo.comREPL Feb 2024 30.000 putDecember 8, 2023 | markets.businessinsider.comBalanced Outlook: Replimune’s Setbacks and Potential in Clinical Trials Justify Buy RatingDecember 7, 2023 | finance.yahoo.comAn Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% UndervaluedDecember 7, 2023 | markets.businessinsider.comOptimistic Buy Rating on Replimune Group Focused on RP1’s Melanoma Treatment Potential and Strategic RealignmentDecember 5, 2023 | msn.comReplimune shares crash as skin cancer candidate fails trialDecember 5, 2023 | msn.comReplimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goalsDecember 5, 2023 | reuters.comReplimune's skin cancer drug fails in mid-stage studyDecember 5, 2023 | markets.businessinsider.comWhat's Going On With Cancer-Focused Replimune Stock Today?December 5, 2023 | finance.yahoo.comReplimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin CancersDecember 5, 2023 | marketbeat.comTrading was temporarily halted for "REPL" at 06:12 AM with a stated reason of "News pending."November 26, 2023 | benzinga.comReplimune Group Stock (NASDAQ:REPL) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comReplimune Group Stock (NASDAQ:REPL), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK), Replimune Group (REPL) and Precision BioSciences (DTIL)November 8, 2023 | finance.yahoo.comReplimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma ResearchNovember 7, 2023 | msn.comReplimune Group GAAP EPS of -$0.90 misses by $0.04November 7, 2023 | finance.yahoo.comReplimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. REPL Media Mentions By Week REPL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.810.55▲Average Medical News Sentiment REPL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼32▲REPL Articles Average Week Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TScan Therapeutics News Alvotech News Tourmaline Bio News Ocugen News Fate Therapeutics News Lexeo Therapeutics News iTeos Therapeutics News Solid Biosciences News Adaptive Biotechnologies News Taysha Gene Therapies News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressWATCH: The Truth About InflationBirch GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
